New drug combo for certain types of leukemia in remission
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called BEBT-908 plus chemotherapy for people with acute lymphoblastic leukemia that has a specific genetic change (MEF2D) or a certain immune type (pre-B). It's for patients whose leukemia is in remission but still has detectable tiny amounts of disease (MRD positive).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell acute lymphoblastic leukemia with a MEF2D gene rearrangement OR a pre-B immunophenotype (a specific cell type) that is Philadelphia chromosome negative.
- Your leukemia is in complete remission (less than 5% blasts in bone marrow) but there are still minimal residual disease (MRD) cells detected (at least 1 cancer cell in 10,000).
- You are able to take care of yourself (ECOG 0-2) and expected to live more than 3 months.
- Your heart, liver, and kidneys are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called obecabtagene autoleucel (a 'living drug' made from your own immune cells) for people with a type of blood cancer (B-cell ALL) that has responded to initial treatment but may still have tiny traces. The goal is to see if it can prevent relapse after remission.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
This trial tests a combination of drugs (venetoclax, azacitidine, chidamide, vindesine, and dexamethasone) in people newly diagnosed with a rare subtype of T-cell acute lymphoblastic leukemia called ETP-ALL or near-ETP-ALL. The goal is to see if this drug cocktail can improve outcomes.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a combination of four drugs (FLAG-IDA, venetoclax, asciminib, and possibly blinatumomab) for people with chronic myeloid leukemia or acute myeloid leukemia that carry a specific genetic change called the Philadelphia chromosome. The goal is to see if this combination can help people achieve remission and improve survival.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.